CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society

Table 1 General information about headache practice

Item	mean ± standard deviation	median [Q1, Q3]
Length of the headache patients' first appointments, min	23.5 ± 9.5	20 [15, 30]
Length of the headache patients' follow-up appointments, min	9.0 ± 3.9	10 [5, 10]
No. of patients with migraine who are followed up regularly^a	121.8 ± 263.7	30 [15, 100]
No. of patients with migraine who are followed up regularly and have ever used preventive treatments^a	77.1 ± 165.7	20 [9, 67.5]
Any experience using CGRPmAbs	Yes: 320 (80.6%)
No. of patients with migraine who are followed up regularly and have ever used CGRPmAbs^b	25.5 ± 45.9	10 [4, 25]

The data are presented as mean ± standard deviation and median [first quartile (Q1), third quartile (Q3)] (n = 397)
^aNine answers were excluded (n = 388)
^bEight answers were excluded (n = 312). CGRPmAb: anti-calcitonin gene-related peptide monoclonal antibody, min: minute, No.: number

ISSN: 1129-2377